Kaifeng Pharmaceutical Group Co Ltd

Kaifeng Pharmaceutical Group Co., Ltd, founded in May 1949, is one of central China’s leading pharmaceutical enterprises. With a rich history stretching back over seven decades, the company develops, manufactures, and exports a wide range of pharmaceutical products spanning active pharmaceutical ingredients (APIs), finished formulations, and sterile preparations. Headquartered in Kaifeng, Henan Province, the company maintains multiple large-scale production lines and a workforce of over 2,000 employees, underlining its significance in both the domestic and global pharmaceutical industries.

Comprehensive Product Portfolio

Kaifeng Pharmaceutical Group offers more than 300 formulations and nearly 50 APIs, making it a major supplier across multiple therapeutic areas. Its APIs include critical compounds such as gentamicin sulfate, doxycycline hyclate (monohydrate), piroxicam, fenofibrate, lansoprazole, and levofloxacin mesylate.

Key Product Categories

• Antibiotics and semi-synthetic antibiotics (e.g., gentamicin sulfate, doxycycline)
• Anti-inflammatory and lipid-lowering agents (e.g., piroxicam, fenofibrate)
• Gastrointestinal medications (e.g., lansoprazole)
• Quinolone antibiotics (e.g., levofloxacin mesylate)
• Wide range of finished dosage forms, including injectables, tablets, eye drops, creams, and granules

Doxycycline hyclate, in particular, holds EU GMP certification since 2012 and has been exported to European markets for over three decades.

Manufacturing Capabilities and Certifications

The group’s manufacturing site, located in Kaifeng, spans approximately 400,000 square meters with over 170,000 square meters of constructed area. Their facility is equipped with over 3,000 units of advanced production equipment.

Production and Quality Infrastructure

• Annual API production exceeds 300 metric tons, plus polypeptide APIs and sterile APIs.
• Full GMP certifications across multiple product lines, reinforcing quality consistency.
• Recognition as a high-tech enterprise in Henan Province with robust quality assurance systems.
• First pharmaceutical enterprise in Henan authorized for independent import/export by the China Ministry of Foreign Trade and Economic Cooperation.

Scale of Operations and Human Resources

The company employs approximately 2,000 to 2,100 staff, including a strong technical and R&D workforce. One profile lists over 2,118 employees , .

Export Footprint and Market Reach

Kaifeng Pharmaceutical exports its APIs and formulations to more than 70 countries and regions, including markets in the United States, Japan, Europe, Africa, and Southeast Asia.

Corporate Development and Ownership

Kaifeng Pharmaceutical began as a state-owned factory and evolved into a limited liability group enterprise. In 2015, it was acquired by Furen Pharmaceutical Group Industry Co., Ltd., in a deal valuing approximately $1.2 billion.

Ownership and Corporate Structure

• Originally established in 1949; incorporated in its group form in 2003.
• Currently a private limited company with registered capital over RMB 200 million.
• Major shareholder: Furen Group Pharmaceutical Co., Ltd. following the 2015 acquisition.

Research and Development Efforts

With nearly 50 APIs and over 300 formulations, Kaifeng Pharma maintains active R&D operations that align with its production capabilities. The company supports its growth through investment in process development, analytical methodology, quality control, and compliance. Their ability to meet international pharmacopeia standards shows a sustained emphasis on innovation and regulatory alignment.

R&D Highlights

• Continuous EU-GMP compliance for key products like doxycycline hyclate since 2012.
• Regular quality certifications from national and local drug supervision departments, maintaining 100% pass rates for over 19 years.
• API pipelines targeting global pharmaceutical standards and emerging therapeutic needs.

Role in Henan and National Pharma Industry

As a recognized high-tech and export-oriented enterprise in Henan Province, Kaifeng Pharmaceutical has played a crucial role in regional economic development. It stands among the top 100 medical enterprises in China. Its export-first strategy and regulatory credentials have made it a key participant in China’s pharmaceutical modernization and global integration efforts.

Impact on Local Economy

• Significant employer in Kaifeng and surrounding regions.
• Drives infrastructure growth with large-scale manufacturing investments.
• Stabilizes regional export performance through diversified pharmaceutical sales.

Challenges and Future Outlook

Going forward, Kaifeng Pharmaceutical will need to navigate challenges including stringent international regulations, global competition, and evolving industry standards. Its merger with Furen Group positions it well to expand R&D, improve market presence, and pursue portfolio diversification into newer therapeutic areas or biologics.

Prospects Ahead

• Leveraging merger synergies for expanded API development and biosimilar production.
• Entering new international markets through strategic partnerships and certification efforts.
• Scaling up production of sterile preparations and specialized dosage forms.
• Continued investment in quality assurance, regulatory compliance, and innovation.

Kaifeng Pharmaceutical Group Co., Ltd has evolved from a mid-century provincial factory to a modern pharmaceutical powerhouse. With extensive API production, a broad formulation range, strong export networks, and compliance with global pharmacopeias, the company excels in both scale and quality. Its acquisition by Furen Group and ongoing R&D investments signal a promising future. As the global pharmaceutical industry grows ever more complex, Kaifeng Pharma’s established infrastructure, market presence, and forward-looking strategy position it well to thrive in coming years.